RxSight, Inc. (NASDAQ:RXST) Position Trimmed by Royce & Associates LP

Royce & Associates LP lowered its stake in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 47.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,402 shares of the company's stock after selling 42,020 shares during the quarter. Royce & Associates LP owned approximately 0.13% of RxSight worth $2,343,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in RXST. Marshall Wace LLP acquired a new position in RxSight in the second quarter worth $19,512,000. Driehaus Capital Management LLC boosted its holdings in RxSight by 74.9% in the second quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company's stock worth $42,490,000 after purchasing an additional 302,367 shares during the period. Baillie Gifford & Co. boosted its holdings in RxSight by 438.8% in the second quarter. Baillie Gifford & Co. now owns 358,215 shares of the company's stock worth $21,554,000 after purchasing an additional 291,733 shares during the period. William Blair Investment Management LLC acquired a new position in RxSight in the second quarter worth $14,942,000. Finally, Bank of Montreal Can acquired a new position in RxSight in the second quarter worth $5,446,000. Institutional investors and hedge funds own 78.78% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Jefferies Financial Group assumed coverage on RxSight in a research note on Tuesday, October 29th. They issued a "buy" rating and a $72.00 target price on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $66.00 target price on shares of RxSight in a research note on Friday, September 13th. Oppenheimer cut their target price on RxSight from $72.00 to $65.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 6th. Stifel Nicolaus cut their target price on RxSight from $70.00 to $65.00 and set a "buy" rating on the stock in a research note on Tuesday, August 6th. Finally, Wells Fargo & Company cut their target price on RxSight from $68.00 to $54.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 6th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $61.63.

Insider Buying and Selling

In related news, Director Jesse Anderson Corley purchased 11,111 shares of the company's stock in a transaction that occurred on Tuesday, November 12th. The shares were purchased at an average price of $45.37 per share, with a total value of $504,106.07. Following the purchase, the director now owns 468,571 shares of the company's stock, valued at $21,259,066.27. This trade represents a 2.43 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Ilya Goldshleger sold 3,100 shares of RxSight stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $53.19, for a total value of $164,889.00. Following the completion of the transaction, the insider now directly owns 42,246 shares in the company, valued at $2,247,064.74. This represents a 6.84 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 52,720 shares of company stock valued at $2,603,950 over the last three months. Company insiders own 9.36% of the company's stock.

RxSight Price Performance

Shares of NASDAQ RXST traded down $0.47 during midday trading on Wednesday, reaching $44.65. 70,788 shares of the company traded hands, compared to its average volume of 488,570. The stock has a 50-day moving average price of $49.97 and a 200 day moving average price of $53.04. The company has a market cap of $1.80 billion, a price-to-earnings ratio of -53.43 and a beta of 1.19. RxSight, Inc. has a 52 week low of $27.51 and a 52 week high of $66.54.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.